BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Collaboration

  Lilly Signs Back-to-Back Deals in MASH, Cancer

  Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals and another for cancer therapies with Australia’s AdvanCell.

  February 11, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Delivery

  Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss

  Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing potential risks to the public.

  February 11, 2025

   · 

  5 min read

   · 

  Ben Hargreaves
• 

  Layoffs

  Inventiva to Halve Its Workforce, Shift Focus to MASH Candidate

  French biotech Inventiva’s layoffs and pipeline shift are expected to help keep the company operational into the second half of 2026.

  February 11, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Pain

  Vertex Eyes Expansive, Easy Access for Journavx in Coming Weeks

  Vertex expects to make the newly approved non-opioid pain medicine Journavx available by the end of February.

  February 11, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout

  Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.

  February 11, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Prostate cancer

  Leaked Conference Article Shows Pfizer’s Positive Phase I Prostate Cancer Data

  A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating castration-resistant prostate cancer.

  February 11, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Mergers & acquisitions

  Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition

  Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

  February 11, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Qu Biologics’ Immunomodulator Clears Senescence

  February 11, 2025

   · 

  5 min read
• Press Releases

  Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025

  February 11, 2025

   · 

  4 min read
• Press Releases

  Tevogen Bio’s Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

  February 11, 2025

   · 

  5 min read